Literature DB >> 27466822

Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers - United States, 2010-2015.

Mehruba Anwar1, Royal Law, Josh Schier.   

Abstract

Kratom (Mitragyna speciosa) is a plant consumed throughout the world for its stimulant effects and as an opioid substitute (1). It is typically brewed into a tea, chewed, smoked, or ingested in capsules (2). It is also known as Thang, Kakuam, Thom, Ketum, and Biak (3). The Drug Enforcement Administration includes kratom on its Drugs of Concern list (substances that are not currently regulated by the Controlled Substances Act, but that pose risks to persons who abuse them), and the National Institute of Drug Abuse has identified kratom as an emerging drug of abuse (3,4). Published case reports have associated kratom exposure with psychosis, seizures, and deaths (5,6). Because deaths have been attributed to kratom in the United States (7), some jurisdictions have passed or are considering legislation to make kratom use a felony (8). CDC characterized kratom exposures that were reported to poison centers and uploaded to the National Poison Data System (NPDS) during January 2010-December 2015. The NPDS is a national database of information logged by the country's regional poison centers serving all 50 United States, the District of Columbia, and Puerto Rico and is maintained by the American Association of Poison Control Centers. NPDS case records are the result of call reports made by the public and health care providers.

Entities:  

Mesh:

Year:  2016        PMID: 27466822     DOI: 10.15585/mmwr.mm6529a4

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  29 in total

Review 1.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

2.  A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdue.

Authors:  David V Gauvin; Zachary J Zimmermann
Journal:  Psychopharmacology (Berl)       Date:  2018-11-10       Impact factor: 4.530

Review 3.  Current regulatory guidelines and resources to support research of dietary supplements in the United States.

Authors:  Regan L Bailey
Journal:  Crit Rev Food Sci Nutr       Date:  2018-11-13       Impact factor: 11.176

4.  Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Justin C Strickland
Journal:  J Psychoactive Drugs       Date:  2021-11-29

5.  Posterior reversible leukoencephalopathy syndrome after kratom ingestion.

Authors:  Austin Castillo; J Drew Payne; Kenneth Nugent
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

Review 6.  Substance-induced Psychosis in Youth.

Authors:  David Beckmann; Kelsey Leigh Lowman; Jessica Nargiso; James McKowen; Lisa Watt; Amy M Yule
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2019-09-23

Review 7.  Breakthrough Seizure Associated With Kratom Use in Patients With Epilepsy.

Authors:  Devin J Burke; Sarah G Mahonski; Anne C Van Cott
Journal:  Neurol Clin Pract       Date:  2021-02

8.  Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey.

Authors:  Rhiannon Bath; Tanner Bucholz; Amy F Buros; Darshan Singh; Kirsten E Smith; Charles A Veltri; Oliver Grundmann
Journal:  J Addict Med       Date:  2020 May/Jun       Impact factor: 4.647

9.  Prevalence of Kratom Use and Co-Occurring Substance Use Disorders in the United States.

Authors:  Kevin Y Xu; Carrie M Mintz; Jacob T Borodovsky; Paul E A Glaser; Laura J Bierut; Richard A Grucza
Journal:  Prim Care Companion CNS Disord       Date:  2021-08-05

Review 10.  A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.

Authors:  Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers
Journal:  Hum Psychopharmacol       Date:  2021-07-26       Impact factor: 2.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.